Miraculins Announces Thermo Fisher Scientific as Key Manufacturing Partner
Miraculins Inc. has announced that it has completed an Exclusive Manufacturing and Supply Agreement with Thermo Fisher Scientific Inc.. Under the agreement, Thermo Fisher will supply the PreVu Non-Invasive Skin Cholesterol Test reagents and testing kits.
The parties have outlined a three-stage technical process ending with the production of commercial reagent kits for distribution to customers.
Miraculins reports that the first stage of that process has successfully been completed, and production is progressing efficiently towards commercially available product.
PreVu is a non-invasive risk assessment technology that evaluates the additional risk a person may have for coronary artery disease (CAD) by conveniently and painlessly testing their skin cholesterol level.
High levels of skin cholesterol have been shown to be correlated to CAD as measured by stress test, angiography, coronary calcium, and carotid intima-media thickness, inflammatory markers of vascular disease, previous heart attack incidents and Framingham risk score.
Thermo Fisher previously manufactured PreVu reagents and test kits when the technology's former owner first test marketed the products. Now, Thermo Fisher will be responsible for the manufacturing and assembly of PreVu Point of Care (POC) test kits and the supply of reagents for the PreVu Lab Processed (LP) Test.
The PreVu LP test is being developed in partnership with Gamma-Dynacare Medical Laboratories, one of Canada's largest and most respected providers of laboratory services.
"We are very pleased to once again be a key manufacturing partner for the PreVu test," said Kathy Napier, divisional director, business development for Thermo Fisher's clinical diagnostics business. "We have been impressed by Miraculins' vision, the potential of this technology and the commitment of their team to bring it to market."
"With Thermo Fisher as our manufacturing partner, we truly have a world-class organization attending to the critical manufacturing and supply of our test kits", stated Christopher Moreau, President & CEO of Miraculins Inc.
Moreau continued, "As Miraculins continues to execute its plan to bring the PreVu technology to market, our relationships with companies like Thermo Fisher reflect the high standards we are committed to in the commercialization of this revolutionary new coronary artery disease risk assessment technology."